biostudies-literatureZou FNCI NIH HHSNational Institutes of Healthe003277https://www.ebi.ac.uk/biostudies/studies/S-EPMC8601082biostudies-literatureUnknown9(11)<h4>Background</h4>Current treatment guidelines for immune-mediated diarrhea and colitis (IMDC) recommend steroids as first-line therapy, followed by selective immunosuppressive therapy (SIT) (infliximab or vedolizumab) for refractory cases. We aimed to compare the efficacy of these two SITs and their impact on cancer outcomes.<h4>Methods</h4>We performed a two-center, retrospective observational cohort study of patients with IMDC who received SITs following steroids from 2016 to 2020. Patients' demographic, clinical, and overall survival data were collected and analyzed.<h4>Results</h4>A total of 184 patients (62 vedolizumab, 94 infliximab, 28 combined sequentially) were included. The efficacy of achieving clinical remission of IMDC was similar (89% vs 88%, p=0.79) between the two groups.Journal for immunotherapy of cancerEfficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study.PMC8601082P30 CA008748Sharon ERichards DMThomas AErnstoff MSThompson JHanauer SZou FSatish DGlitza Oliva ICShah AFaleck DCharabaty AWang XHarris JWang YMcQuade JObeid MWolchok JfalseEfficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study.<h4>Background</h4>Current treatment guidelines for immune-mediated diarrhea and colitis (IMDC) recommend steroids as first-line therapy, followed by selective immunosuppressive therapy (SIT) (infliximab or vedolizumab) for refractory cases. We aimed to compare the efficacy of these two SITs and their impact on cancer outcomes.<h4>Methods</h4>We performed a two-center, retrospective observational cohort study of patients with IMDC who received SITs following steroids from 2016 to 2020. Patients' demographic, clinical, and overall survival data were collected and analyzed.<h4>Results</h4>A total of 184 patients (62 vedolizumab, 94 infliximab, 28 combined sequentially) were included. The efficacy of achieving clinical remission of IMDC was similar (89% vs 88%, p=0.79) between the two groups.2021-01-01T00:00:00Z2021 Nov2026-06-10T05:48:36.801Z2022-02-11T13:34:21.408ZS-EPMC86010823478955110.1136/jitc-2021-003277